Anavex Life Sciences Corp (AVXL)

[falconer66a]

Anavex Will Not Sellout Its Drug Manufacture

We have been told the cost of producing 2-73 is low which means margins will be high and the cost to the patient will be comparatively low.

This is the case. The Anavex molecules are small, uncomplicated, and not difficult to synthesize (manufacture). And Anavex has patents that protect their efficient manufacturing processes, which they can license out to chemical contractors who will bid on those patent-use rights.

Other approved Alzheimer’s drugs are monoclonal antibodies, which prompt the immune system to attack and destroy targeted molecules that cause or are associated with Alzheimer’s disease. But, not cheap. One report telling the production of monoclonal antibodies for the COVID-19 virus stated, “These therapies cost about $2,000 a dose, which includes only about a gram of each antibody.”
https://www.knoxnews.com/story/news/2021/10/04/monoclonal-antibodies-expensive-hard-manufacture-covid-coronavirus/5887418001/

There is no need whatsoever for Anavex to fractionally sellout the manufacture of its drugs to an existing Big Pharma. Instead, they can contract, competitively, with any number of chemical manufacturers to have them both synthesize and package blarcamesine or Anavex 3-71. Dollars a dose costs; not hundreds or thousands of dollars. Doses will be in the range of 10 to 50 milligrams — tiny amounts. A large raindrop can weigh up to 300 milligrams.
https://weightofstuff.com/things-that-weigh-a-milligram/